Comparative Pharmacology
Head-to-head clinical analysis: AVALIDE versus SACUBITRIL AND VALSARTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVALIDE versus SACUBITRIL AND VALSARTAN.
AVALIDE vs SACUBITRIL AND VALSARTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Avalide is a combination of an angiotensin II receptor blocker (irbesartan) and a thiazide diuretic (hydrochlorothiazide). Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- symporter in the distal convoluted tubule.
Sacubitril inhibits neprilysin, increasing natriuretic peptides; Valsartan blocks angiotensin II type 1 receptor, reducing vasoconstriction and aldosterone release. Combined, they enhance vasodilation, decrease sympathetic activity, and reduce cardiac remodeling.
AVALIDE (irbesartan/hydrochlorothiazide) is available as tablets containing 150/12.5 mg, 300/12.5 mg, or 300/25 mg. The typical starting dose is 150/12.5 mg once daily, titrated to 300/12.5 mg once daily as needed. Maximum dose is 300/25 mg once daily.
Initial dose: 24 mg/26 mg (sacubitril 24 mg/valsartan 26 mg) orally twice daily, then double at 2- to 4-week intervals to target maintenance dose of 97 mg/103 mg twice daily.
None Documented
None Documented
Irbesartan: 11-15 h (terminal), HCTZ: 6-15 h (terminal). Clinical context: Steady state reached in 3-5 days; allows once-daily dosing.
Sacubitrilat terminal half-life is approximately 11.5 hours; valsartan terminal half-life is approximately 9.9 hours. Twice-daily dosing maintains therapeutic concentrations.
Renal: HCTZ ~70% unchanged; Irbesartan ~20% unchanged, remainder as metabolites via biliary (60%) and renal (20%). Combined: Renal ~50%, biliary/fecal ~50%.
Sacubitril is converted to sacubitrilat, which is primarily eliminated renally (52–68% as sacubitrilat) and via biliary/fecal routes (37–48% as metabolites). Valsartan is predominantly eliminated via biliary/fecal route (83%) with renal elimination accounting for 13%.
Category C
Category D/X
ARB and Thiazide Diuretic Combination
ARB